Emerging Plasmodium falciparum K13 gene mutation to artemisinin-based combination therapies and partner drugs among malaria-infected population in sub-Saharan Africa
Parasites, Hosts and Diseases · 2025
DOI: 10.3347/phd.24053 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Parasites, Hosts and Diseases, 2025. Verfasst von Samuel Adeniyi Oyegbade und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, College of Science and Technology, Covenant University, Ota 112233, Nigeria. Hauptthemen laut MEDLINE: Plasmodium falciparum, Artemisinins, Antimalarials, Malaria, Falciparum. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Covenant University Centre for Research, Innovation and Discovery.
Abstract (Originalsprache)
The continuous Plasmodium falciparum kelch13 (PfK13) genetic alterations conferring resistance to artemisinin-based combination therapies and partner drugs pose a significant threat to effective treatment and control of P. falciparum infection in developing countries. This review evaluates the emergence and epidemiology of the PfK13 mutation associated with artemisinin resistance in the sub-Saharan Africa (SSA) population. Despite empirical control and artemisinin combination therapy, the PfK13 gene mutation, previously described in Southeast Asia, has been reported in the SSA. Eight of these validated markers, including P553L, M476I, C580Y, A675V, P574L, R561H, R622I, and F446I, were reported among the SSA population. Novel and unvalidated markers, such as P615S, M472I, F434S, A578S, P570L, Y558C, K563R, A569T, I684N, M472I, and C473F spread among the population with low frequency. We provide insight into the emergence and spread of validated and unvalidated PfK13 mutations among the SSA population, which could lead to high artemisinin resistance. Investigating the verified PfK13 mutations will improve prophylactic strategies, prognostic diagnosis and guide effective population-based surveillance for effective P. falciparum malaria control in SSA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Sciences, College of Science and Technology, Covenant University, Ota 112233, Nigeria.
- Covenant Applied Informatics and Communication Africa Centre of Excellence (CApIC-ACE), Covenant University, Ota 112233, Nigeria.
- Department of Medical Laboratory Science, Babcock University, Illishan 121103, Nigeria.
Förderung
- Covenant University Centre for Research, Innovation and Discovery
Zitieren
APA
Oyegbade, S. A., Mameh, E. O., Balogun, D. O., Aririguzoh, V. O., & Akinduti, P. A. (2025). Emerging Plasmodium falciparum K13 gene mutation to artemisinin-based combination therapies and partner drugs among malaria-infected population in sub-Saharan Africa. Parasites, Hosts and Diseases. https://doi.org/10.3347/phd.24053
Vancouver
Oyegbade SA, Mameh EO, Balogun DO, Aririguzoh VO, Akinduti PA. Emerging Plasmodium falciparum K13 gene mutation to artemisinin-based combination therapies and partner drugs among malaria-infected population in sub-Saharan Africa. Parasites, Hosts and Diseases. 2025. doi:10.3347/phd.24053
BibTeX
@article{Oyegbade2025,
author = {Oyegbade, Samuel Adeniyi and Mameh, Emmanuel Ojochegbe and Balogun, Daniel Oluwatobiloba and Aririguzoh, Victoria-Grace Onyekachi and Akinduti, Paul Akinniyi},
title = {Emerging Plasmodium falciparum K13 gene mutation to artemisinin-based combination therapies and partner drugs among malaria-infected population in sub-Saharan Africa},
journal = {Parasites, Hosts and Diseases},
year = {2025},
doi = {10.3347/phd.24053}
}
EUVIMED